Last reviewed · How we verify
Artemether-lumefantrine 3 days
Artemether-lumefantrine is a fixed-dose combination antimalarial that kills malaria parasites through multiple mechanisms: artemether rapidly reduces parasite biomass while lumefantrine eliminates remaining parasites and prevents recrudescence.
Artemether-lumefantrine is a fixed-dose combination antimalarial that kills malaria parasites through multiple mechanisms: artemether rapidly reduces parasite biomass while lumefantrine eliminates remaining parasites and prevents recrudescence. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions.
At a glance
| Generic name | Artemether-lumefantrine 3 days |
|---|---|
| Also known as | Coartem®, Novatis, Switzerland |
| Sponsor | University of Oxford |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Plasmodium falciparum parasites; artemether targets multiple parasite proteins; lumefantrine inhibits heme polymerization |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Artemether, a semi-synthetic artemisinin derivative, generates reactive oxygen species that damage parasite proteins and DNA, providing rapid parasite clearance. Lumefantrine, a biguanide-like compound, inhibits parasite heme polymerization and mitochondrial function, providing sustained antimalarial activity. The 3-day regimen is a shortened treatment course compared to standard 6-dose regimens, designed to improve adherence while maintaining efficacy.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria treatment in endemic regions
Common side effects
- Headache
- Fever
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Dizziness
Key clinical trials
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) (PHASE2)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria (PHASE3)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women (NA)
- Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics (PHASE4)
- Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artemether-lumefantrine 3 days CI brief — competitive landscape report
- Artemether-lumefantrine 3 days updates RSS · CI watch RSS
- University of Oxford portfolio CI